Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia
Paik Ling Chuah,1 Nurnina Fareeha Jamal,1 Chai Jin Siew,1 Ros Suzanna Ahmad Bustamam,2 Vaishnavi Jeyasingam,2 Khei Choong Khong3 1Department of Pharmacy, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, Malaysia; 2Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Ministry of He...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-09-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/assessment-of-adherence-to-imatinib-and-health-related-quality-of-life-peer-reviewed-fulltext-article-PPA |
| _version_ | 1818908692221788160 |
|---|---|
| author | Chuah PL Jamal NF Siew CJ Ahmad Bustamam RS Jeyasingam V Khong KC |
| author_facet | Chuah PL Jamal NF Siew CJ Ahmad Bustamam RS Jeyasingam V Khong KC |
| author_sort | Chuah PL |
| collection | DOAJ |
| description | Paik Ling Chuah,1 Nurnina Fareeha Jamal,1 Chai Jin Siew,1 Ros Suzanna Ahmad Bustamam,2 Vaishnavi Jeyasingam,2 Khei Choong Khong3 1Department of Pharmacy, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, Malaysia; 2Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, Malaysia; 3Department of Pharmacy, National Cancer Institute, Ministry of Health, Putrajaya, MalaysiaCorrespondence: Paik Ling ChuahDepartment of Pharmacy, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, MalaysiaTel +60 3 2615 5834Email paik_ling@moh.gov.myPurpose: To evaluate the rate and predictors of non-adherence to imatinib in gastrointestinal stromal tumor (GIST) patients, as well as to compare the difference in health-related quality of life (HRQOL) between adherent and non-adherent patients.Patients and Methods: A cross-sectional study at the Oncology Clinic, Hospital Kuala Lumpur was conducted from March to August 2018. All patients with metastatic and/or unresectable GIST aged ≥ 18 years old and on at least 3 months of imatinib were included. Adherence to imatinib was assessed using the 10-item validated Medication Compliance Questionnaire, with a score of < 100% indicating non-adherence. Non-adherence predictors were determined by multiple logistic regressions. HRQOL was evaluated by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The difference in the mean HRQOL scores between adherent and non-adherent groups was determined by multivariate analysis of variance.Results: A total of 89 patients were enrolled, of which 49 (55.1%) were considered non-adherent. The significant predictors of non-adherence were age (adjusted odds ratio [OR] 0.93; CI 0.89– 0.98; P = 0.007), presence of nausea and vomiting (OR 5.63; CI 1.25– 25.27; P = 0.024), and presence of comorbidities (OR 4.56; CI 1.44– 14.40; P = 0.010). Patients who were in the adherent group showed significantly better score in overall HRQOL, F (15, 73) = 2.09, P < 0.02; Pillai’s trace = 0.3, partial eta squared = 0.30.Conclusion: Non-adherence to long-term treatment with imatinib among patients with GIST should not be underestimated. Significant predictors of non-adherence among this population are younger age, presence of nausea and vomiting, as well as comorbidities. Patients with good adherence portrayed better HRQOL.Keywords: compliance, imatinib, gastrointestinal stromal tumor, quality of life |
| first_indexed | 2024-12-19T22:15:03Z |
| format | Article |
| id | doaj.art-9472a90c97644d909c01cd329086749a |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-19T22:15:03Z |
| publishDate | 2021-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-9472a90c97644d909c01cd329086749a2022-12-21T20:03:48ZengDove Medical PressPatient Preference and Adherence1177-889X2021-09-01Volume 152175218469079Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in MalaysiaChuah PLJamal NFSiew CJAhmad Bustamam RSJeyasingam VKhong KCPaik Ling Chuah,1 Nurnina Fareeha Jamal,1 Chai Jin Siew,1 Ros Suzanna Ahmad Bustamam,2 Vaishnavi Jeyasingam,2 Khei Choong Khong3 1Department of Pharmacy, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, Malaysia; 2Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, Malaysia; 3Department of Pharmacy, National Cancer Institute, Ministry of Health, Putrajaya, MalaysiaCorrespondence: Paik Ling ChuahDepartment of Pharmacy, Kuala Lumpur Hospital, Ministry of Health, Kuala Lumpur, MalaysiaTel +60 3 2615 5834Email paik_ling@moh.gov.myPurpose: To evaluate the rate and predictors of non-adherence to imatinib in gastrointestinal stromal tumor (GIST) patients, as well as to compare the difference in health-related quality of life (HRQOL) between adherent and non-adherent patients.Patients and Methods: A cross-sectional study at the Oncology Clinic, Hospital Kuala Lumpur was conducted from March to August 2018. All patients with metastatic and/or unresectable GIST aged ≥ 18 years old and on at least 3 months of imatinib were included. Adherence to imatinib was assessed using the 10-item validated Medication Compliance Questionnaire, with a score of < 100% indicating non-adherence. Non-adherence predictors were determined by multiple logistic regressions. HRQOL was evaluated by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The difference in the mean HRQOL scores between adherent and non-adherent groups was determined by multivariate analysis of variance.Results: A total of 89 patients were enrolled, of which 49 (55.1%) were considered non-adherent. The significant predictors of non-adherence were age (adjusted odds ratio [OR] 0.93; CI 0.89– 0.98; P = 0.007), presence of nausea and vomiting (OR 5.63; CI 1.25– 25.27; P = 0.024), and presence of comorbidities (OR 4.56; CI 1.44– 14.40; P = 0.010). Patients who were in the adherent group showed significantly better score in overall HRQOL, F (15, 73) = 2.09, P < 0.02; Pillai’s trace = 0.3, partial eta squared = 0.30.Conclusion: Non-adherence to long-term treatment with imatinib among patients with GIST should not be underestimated. Significant predictors of non-adherence among this population are younger age, presence of nausea and vomiting, as well as comorbidities. Patients with good adherence portrayed better HRQOL.Keywords: compliance, imatinib, gastrointestinal stromal tumor, quality of lifehttps://www.dovepress.com/assessment-of-adherence-to-imatinib-and-health-related-quality-of-life-peer-reviewed-fulltext-article-PPAcomplianceimatinibgastrointestinal stromal tumorquality of life |
| spellingShingle | Chuah PL Jamal NF Siew CJ Ahmad Bustamam RS Jeyasingam V Khong KC Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia Patient Preference and Adherence compliance imatinib gastrointestinal stromal tumor quality of life |
| title | Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia |
| title_full | Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia |
| title_fullStr | Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia |
| title_full_unstemmed | Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia |
| title_short | Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia |
| title_sort | assessment of adherence to imatinib and health related quality of life among patients with gastrointestinal stromal tumor a cross sectional study in an oncology clinic in malaysia |
| topic | compliance imatinib gastrointestinal stromal tumor quality of life |
| url | https://www.dovepress.com/assessment-of-adherence-to-imatinib-and-health-related-quality-of-life-peer-reviewed-fulltext-article-PPA |
| work_keys_str_mv | AT chuahpl assessmentofadherencetoimatinibandhealthrelatedqualityoflifeamongpatientswithgastrointestinalstromaltumoracrosssectionalstudyinanoncologyclinicinmalaysia AT jamalnf assessmentofadherencetoimatinibandhealthrelatedqualityoflifeamongpatientswithgastrointestinalstromaltumoracrosssectionalstudyinanoncologyclinicinmalaysia AT siewcj assessmentofadherencetoimatinibandhealthrelatedqualityoflifeamongpatientswithgastrointestinalstromaltumoracrosssectionalstudyinanoncologyclinicinmalaysia AT ahmadbustamamrs assessmentofadherencetoimatinibandhealthrelatedqualityoflifeamongpatientswithgastrointestinalstromaltumoracrosssectionalstudyinanoncologyclinicinmalaysia AT jeyasingamv assessmentofadherencetoimatinibandhealthrelatedqualityoflifeamongpatientswithgastrointestinalstromaltumoracrosssectionalstudyinanoncologyclinicinmalaysia AT khongkc assessmentofadherencetoimatinibandhealthrelatedqualityoflifeamongpatientswithgastrointestinalstromaltumoracrosssectionalstudyinanoncologyclinicinmalaysia |